Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy
Euro J of Neurology. 2022-01-27; 29(4): 1025-1034
DOI: 10.1111/ene.15232
Lire sur PubMed
Pavy-Le Traon A(1), Foubert-Samier A(2), Ory-Magne F(3), Fabbri M(3), Senard JM(4), Meissner WG(2)(5)(6), Rascol O(7), Amar J(8).
Author information:
(1)Neurology Department University Hospital of Toulouse and INSERM UMR 1297,
French Reference Center for Multiple System Atrophy, Institute of Cardiovascular
and Metabolic Diseases (I2MC), Toulouse, France.
(2)CRMR AMS, Service de Neurologie – Maladies Neurodégénératives, CHU de
Bordeaux, Bordeaux, France.
(3)Neurology Department University Hospital of Toulouse, Clinical Investigation
Center CIC 1436, Parkinson Expert Centre, French Reference Center for Multiple
System Atrophy, NeuroToul Center of Excellence in Neurodegeneration (COEN) of
Toulouse, CHU of Toulouse, INSERM, University of Toulouse 3, Toulouse, France.
(4)Department of Clinical Pharmacology, Institute of Cardiovascular and
Metabolic Diseases (I2MC), Toulouse University Hospital and INSERM UMR 1297,
Toulouse, France.
(5)CNRS, IMN, UMR 5293, Univ. Bordeaux, Bordeaux, France.
(6)Department of Medicine, New Zealand Brain Research Institute, University of
Otago, Christchurch, New Zealand.
(7)French Reference Center for Multiple System Atrophy, Clinical Investigation
Center CIC1436, Department of Clinical Pharmacology and Neurosciences, NeuroToul
Center of Excellence in Neurodegeneration (COEN) of Toulouse, CHU of Toulouse,
INSERM and University of Toulouse 3, Toulouse, France.
(8)Department of arterial hypertension, European Society of Hypertension
Excellence Center, INSERM UMR 1047, Toulouse University, Toulouse, France.